Listing of the Claims

This listing of claims will replace all prior versions and listings of the claims in the application:

1. (Previously Presented) An article for use in an aerosol device, for producing an aerosol, comprising a heat conductive substrate having a surface with a surface area, and a film comprising a drug composition on the surface, the film having a film thickness, wherein the drug composition and film thickness are selected from the group consisting of the following combinations:

alprazolam, film thickness between 0.1 and 10 μm;
amoxapine, thickness between 2 and 20 μm;
apomorphine HCl, film thickness between 0.1 and 5 μm;
atropine, film thickness between 0.1 and 10 μm;
budesonide, film thickness between 0.05 and 20 μm;
bumetanide film thickness between 0.1 and 5 μm;
buprenorphine, film thickness between 0.05 and 10 μm;
butorphanol, film thickness between 0.1 and 10 μm;
celecoxib, film thickness between 2 and 20 μm;
chlorpheniramine, film thickness between 0.05 and 20 μm;
ciclesonide, film thickness between 0.05 and 5 μm;
clomipramine, film thickness between 1 and 8 μm;
diazepam, film thickness between 0.05 and 20 μm;
diphenhydramine, film thickness between 0.05 and 20 μm;
donepezil, film thickness between 1 and 10 μm;
eletriptan, film thickness between 0.2 and 20 μm;
fentanyl, film thickness between 0.05 and 5 μm;
granisetron, film thickness between 0.05 and 20 μm;
hydromorphone, film thickness between 0.05 and 10 μm;
lorazepam, film thickness between 0.05 and 20 μm;
loxapine, film thickness between 1 and 20 μm;

midazolam, film thickness between 0.05 and 20 μm;
morphine, film thickness between 0.2 and 10 μm;
nalbuphine, film thickness between 0.2 and 5 μm;
naratriptan, film thickness between 0.2 and 5 μm;
olanzapine, film thickness between 1 and 20 μm;
parecoxib, film thickness between 0.5 and 2 μm;
paroxetine, film thickness between 1 and 20 μm;
prochlorperazine, film thickness between 0.1 and 20 μm;
quetiapine, film thickness between 1 and 20 μm;
ropinirole, film thickness between 0.05 and 20 μm;
sertraline, film thickness between 1 and 20 μm;
sibutramine, film thickness between 0.5 and 2 μm;
sildenafil, film thickness between 0.2 and 3 μm;
sumatriptan, film thickness between 0.2 and 6 μm;
tadalafil, film thickness between 0.2 and 5 μm;
valdecoxib, film thickness between 0.5 and 10 μm; and
vardenafil, film thickness between 0.1 and 2 μm;
venlafaxine, film thickness between 2 and 20 μm;
zaleplon, film thickness between 0.05 and 20 μm; and
zolpidem, film thickness between 0.1 and 10 μm;

wherein an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized drug composition contains 10% by weight or less drug degradation products and at least 50% of the total amount of drug composition in the film, and wherein the substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol.

2. (Previously Presented) The article of claim 1, wherein said substrate surface area is between about 0.05-100 cm^2.

3. (Previously Presented) The article of claim 1, wherein said substrate surface is impermeable.

4. (Previously Presented) The article of claim 1, wherein said substrate comprises a material selected from the group consisting of metals, polymers, ceramics, and glass.

5. (Previously Presented) The article of claim 4, wherein said material is a metal selected from the group consisting of stainless steel and aluminum.

6. (Previously Presented) The article of claim 1, wherein said substrate has a contiguous surface area of greater than 1 mm^2 and a material density of greater than 0.5 g/cc.

7. (Previously Presented) The article of claim 1, wherein said aerosol has 5% by weight or less drug degradation products.

8.-14. (Cancelled)

15. (Previously Presented) A method of forming an effective human therapeutic inhalation dose of a drug composition aerosol having 10% or less drug degradation products and an aerosol particle mass median aerodynamic diameter (MMAD) between 0.01 and 3 μm, comprising

(a) providing a heat conductive substrate having a surface with a surface area, and a film comprising a drug composition on the surface, the film having a film thickness, wherein the drug composition and film thickness are selected from the group consisting of the following combinations:

alprazolam, film thickness between 0.1 and 10 μm;
amoxapine, thickness between 2 and 20 μm;
apomorphine HCl, film thickness between 0.1 and 5 μm;
atropine, film thickness between 0.1 and 10 μm;
budesonide, film thickness between 0.05 and 20 μm;
bumetanide film thickness between 0.1 and 5 μm;
buprenorphine, film thickness between 0.05 and 10 μm;
butorphanol, film thickness between 0.1 and 10 μm;
celecoxib, film thickness between 2 and 20 μm;

chlorpheniramine, film thickness between 0.05 and 20 μm;
ciclesonide, film thickness between 0.05 and 5 μm;
clomipramine, film thickness between 1 and 8 μm;
diazepam, film thickness between 0.05 and 20 μm;
diphenhydramine, film thickness between 0.05 and 20 μm;
donepezil, film thickness between 1 and 10 μm;
eletriptan, film thickness between 0.2 and 20 μm;
fentanyl, film thickness between 0.05 and 5 μm;
granisetron, film thickness between 0.05 and 20 μm;
hydromorphone, film thickness between 0.05 and 10 μm;
lorazepam, film thickness between 0.05 and 20 μm;
loxapine, film thickness between 1 and 20 μm;
midazolam, film thickness between 0.05 and 20 μm;
morphine, film thickness between 0.2 and 10 μm;
nalbuphine, film thickness between 0.2 and 5 μm;
naratriptan, film thickness between 0.2 and 5 μm;
olanzapine, film thickness between 1 and 20 μm;
parecoxib, film thickness between 0.5 and 2 μm;
paroxetine, film thickness between 1 and 20 μm;
prochlorperazine, film thickness between 0.1 and 20 μm;
quetiapine, film thickness between 1 and 20 μm;
ropinirole, film thickness between 0.05 and 20 μm;
sertraline, film thickness between 1 and 20 μm;
sibutramine, film thickness between 0.5 and 2 μm;
sildenafil, film thickness between 0.2 and 3 μm;
sumatriptan, film thickness between 0.2 and 6 μm;
tadalafil, film thickness between 0.2 and 5 μm;
valdecoxib, film thickness between 0.5 and 10 μm; and
vardenafil, film thickness between 0.1 and 2 μm;
venlafaxine, film thickness between 2 and 20 μm;
zaleplon, film thickness between 0.05 and 20 μm; and

zolpidem, film thickness between 0.1 and 10 μm;

(b) heating the substrate to a temperature between 300°C and 500°C, thereby vaporizing a at least a portion of the drug composition film, and

(c) flowing a gas during said heating across the substrate at a gas flow rate effective to produce a desired size of aerosol particles by condensation.

16. (Previously Presented) The method according to claim 15, wherein said heating vaporizes the drug composition film on the substrate within a time period of 2 seconds.

17. (Previously Presented) The method according to claim 16, wherein said heating vaporizes the drug composition film on the substrate within a time period of 0.5 seconds.

18. (Previously Presented) The method of claim 15, wherein said flowing is at a gas flow rate of between 4 and 50 L/minute.

19. (Previously Presented) The method of claim 15, wherein the aerosol contains 5% by weight or less drug degradation products.

20.-30 (Cancelled)